Should You Buy Moderna Before Aug. 5?

Moderna's investigational flu vaccine candidate (mRNA-1010) received unanimous FDA advisory panel approval, with a regulatory decision expected by August 5. The stock has surged over 100% this year as the company reaches a key transition point with multiple product launches planned for 2027-2028. However, the analyst suggests waiting for a post-approval dip to buy, as much of the good news may already be priced in.